INTRODUCTION The therapeutic landscape of older acute myeloid leukemia (AML) has rapidly evolved with the introduction of venetoclax-based regimens, molecularly targeted therapies and improved transplant strategies. As complete remission (CR) becomes increasingly achievable in older patients, its actual contribution to long-term survival requires critical reassessment. AREAS COVERED This review examines the biological, clinical and therapeutic determinants of CR in older AML, focusing on disease biology, hypomethylating agents-venetoclax combinations, IDH, FLT3 and menin inhibitors, intensive chemotherapy, allogeneic transplantation and the emerging concept of dynamic fitness. The literature was reviewed through a critical analysis of pivotal clinical trials, real-world studies, guideline recommendations and landmark translational investigations evaluating remission quality, measurable residual disease, treatment tolerability and survival outcomes. EXPERT OPINION In older AML patients, CR should no longer be regarded as a uniform therapeutic endpoint but as a multidimensional therapeutic state whose clinical value depends on disease biology, remission depth, preservation of patient fitness and the opportunity to deliver subsequent disease-modifying therapies. The future challenge in older AML is no longer simply to achieve complete remission, but to achieve the right remission--one capable of translating into meaningful long-term survival while preserving functional independence.
